Literature DB >> 15254794

Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study.

R Ceravolo1, D Volterrani, G Gambaccini, S Bernardini, C Rossi, C Logi, G Tognoni, G Manca, G Mariani, U Bonuccelli, L Murri.   

Abstract

The occurrence of parkinsonism in Alzheimer's disease (AD) is quite common, however the molecular and neurochemical changes underlying such extrapyramidal features in AD have been not fully understood. Post-mortem as well as in vivo imaging study have produced conflicting results as regards the existence of dopaminergic changes in AD. Aim of the present study was to investigate in vivo the nigro-striatal dopaminergic function in a group of AD patients with parkinsonism. Thirteen patients with AD and extrapyramidal features not related to past neuroleptic use (AD-P) underwent SPECT with 123I-FP-CIT, a ligand of dopamine transporter, and the data were compared with those obtained in 15 patients with Diffuse Lewy Body Dementia (DLBD), 20 patients with Parkinson's disease (PD), and 8 healthy elderly controls. The analysis of the data was performed by regions-of-interest approach and calculations of the striatal-to-non specific (occipital lobes) radioactivity ratios were made. The 123I-FP-CIT striatal uptake in patients with AD-P was similar to that obtained in the control population. Both the DLBD and PD groups showed significantly lower 123I-FP-CIT uptake in all striatal areas with respect to AD-P and control groups (p < 0.005). The lack of dopamine transporter changes in our series of AD-P patients can indicate that dopaminergic presynaptic function is preserved in this population and that different dopaminergic changes such as postsynaptic ones, or different neurotransmitter alterations might underlie the extrapyramidal features in AD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254794     DOI: 10.1007/s00702-004-0140-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  10 in total

1.  Nigral Tau pathology and striatal amyloid-β deposition does not correlate with striatal dopamine deficit in Alzheimer's disease.

Authors:  Tabea H Schauer; Maximilian Lochner; Gabor G Kovacs
Journal:  J Neural Transm (Vienna)       Date:  2012-06-05       Impact factor: 3.575

2.  Multimodality imaging characteristics of dementia with Lewy bodies.

Authors:  Kejal Kantarci; Val J Lowe; Bradley F Boeve; Stephen D Weigand; Matthew L Senjem; Scott A Przybelski; Dennis W Dickson; Joseph E Parisi; David S Knopman; Glenn E Smith; Tanis J Ferman; Ronald C Petersen; Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-10-21       Impact factor: 4.673

3.  Distinct FP-CIT PET patterns of Alzheimer's disease with parkinsonism and dementia with Lewy bodies.

Authors:  Seok Jong Chung; Yang Hyun Lee; Han Soo Yoo; Young H Sohn; Byoung Seok Ye; Jungho Cha; Phil Hyu Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-12       Impact factor: 9.236

4.  Regulation of dopamine D₃ receptor in the striatal regions and substantia nigra in diffuse Lewy body disease.

Authors:  J Sun; N J Cairns; J S Perlmutter; R H Mach; J Xu
Journal:  Neuroscience       Date:  2013-06-01       Impact factor: 3.590

5.  Semi-quantitative dopamine transporter standardized uptake value in comparison with conventional specific binding ratio in [123I] FP-CIT single-photon emission computed tomography (DaTscan).

Authors:  Yuichi Wakabayashi; Ryuichi Takahashi; Tomonori Kanda; Feibi Zeng; Munenobu Nogami; Kazunari Ishii; Takamichi Murakami
Journal:  Neurol Sci       Date:  2018-05-10       Impact factor: 3.307

6.  Dopamine Transporter SPECT Imaging in Corticobasal Syndrome.

Authors:  Roberto Cilia; Carlo Rossi; Daniela Frosini; Duccio Volterrani; Chiara Siri; Cristina Pagni; Riccardo Benti; Gianni Pezzoli; Ubaldo Bonuccelli; Angelo Antonini; Roberto Ceravolo
Journal:  PLoS One       Date:  2011-05-02       Impact factor: 3.240

7.  Positive FP-CIT SPECT (DaTSCAN) in Clinical Alzheimer's Disease - An Unexpected Finding?

Authors:  Verena Bittner; Gerhard Ullrich; Markus Thormann; Notger G Müller; Christin Friederichs; Holger Amthauer; Hans-Jochen Heinze; Daniel M Bittner
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2011-09-21

8.  Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study.

Authors:  Mitsuhiro Yoshita; Heii Arai; Hiroyuki Arai; Tetsuaki Arai; Takashi Asada; Hiroshige Fujishiro; Haruo Hanyu; Osamu Iizuka; Eizo Iseki; Kenichi Kashihara; Kenji Kosaka; Hirotaka Maruno; Katsuyoshi Mizukami; Yoshikuni Mizuno; Etsuro Mori; Kenichi Nakajima; Hiroyuki Nakamura; Seigo Nakano; Kenji Nakashima; Yoshiyuki Nishio; Satoshi Orimo; Miharu Samuraki; Akira Takahashi; Junichi Taki; Takahiko Tokuda; Katsuya Urakami; Kumiko Utsumi; Kenji Wada; Yukihiko Washimi; Junichi Yamasaki; Shouhei Yamashina; Masahito Yamada
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

Review 9.  Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT.

Authors:  Lieven D Declercq; Rik Vandenberghe; Koen Van Laere; Alfons Verbruggen; Guy Bormans
Journal:  Front Pharmacol       Date:  2016-03-31       Impact factor: 5.810

10.  Imaging of dopamine transporters in Parkinson disease: a meta-analysis of 18 F/123 I-FP-CIT studies.

Authors:  Yanyan Kong; Chencheng Zhang; Kawai Liu; Aparna Wagle Shukla; Bomin Sun; Yihui Guan
Journal:  Ann Clin Transl Neurol       Date:  2020-08-14       Impact factor: 4.511

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.